Bottom line: BPHAT: Beta-2 agonist, Hypertonic saline, Pulmonzyme, Azithromycin, Tobramycin inhaled
Details: Treatment section of Cystic fibrosis summary in DynaMed.
Table at beginning of the treatment section summarizes evidence for clinical outcomes with use of these medications in patients with cystic fibrosis. Beta-2 agonist is associated with improved expiratory function, Pulmozyme and hypertonic saline are associated with decreases in exacerbations, and tobramycin and azithromycin are associated with reduced risk of hospitalization. See table for fuller description of and links to evidence